|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The aim of this study is to evaluate the possible advantages of liposomes with high transition temperature (Tm) in the function of a vaccine for P5 HER2/neu-generated peptide and its adjuvant action to elicit CD8+ T cell response and its efficacy in TUBO in vivo tumor mice model, which over expresses the HER2/neu oncogene.
|
27411392 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We compared the estrogen- (ER), progesterone- (PgR) and HER2/neu receptor status of the primary tumor with brain metastases in a series of 24 consecutive breast cancer patients.
|
28870906 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The HER2/ERBB2/NEU gene is also frequently overexpressed in breast cancer, and has been shown to promote invasion and metastasis in these tumors.
|
26804171 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
From these studies, we conclude that NEURL1 is a candidate tumor suppressor in MB, at least in part through its effects on the Notch pathway.
|
20847082 |
2010 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
(64)Cu-DOTA-trastuzumab showed a very clear image of a Her2/neu positive tumor and appeared to be effective as a PET tracer for imaging of Her2/neu gene expression in NSCLC, suggesting its potential clinical use for identifying patients that might benefit from trastuzumab-based therapy.
|
20219072 |
2010 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Transgenic BALB-neuT mice vaccinated in late-stage tumor development with a DC vaccine expressing a truncated NEU antigen, IL-I5, and its receptor (DC(Ad.Neu+Ad_mIL-15+Ad.mlL-15Ralpha)) were protected from mammary carcinomas, with 70% of animals tumor-free at 30 weeks compared with none of the animals vaccinated with NEU alone (DC(Ad.Neu)).
|
20086176 |
2010 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
We determined the tumour mutation status of the entire tyrosine kinase (TK) domain of the EGFR and HER2-neu genes in a cohort of 52 patients with invasive epithelial ovarian cancer as well as the gene copy number and protein expression of both genes in 31 of these patients by DGGE and direct sequecing, immunohistochemistry and Fluorescent in Situ Hybridisation (FISH).
|
18182111 |
2008 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The complete concordance between HER2-2/neu protein overexpression and gene amplification was seen only in three of 27 tumors.
|
18415713 |
2008 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Conversely, injection of 5x10(6) NK-92 cells not directed against HER2/neu receptors did not result in increased uptake of radioactivity in the tumors.
|
18589302 |
2008 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Designing a HER2/neu promoter to drive alpha1,3galactosyltransferase expression for targeted anti-alphaGal antibody-mediated tumor cell killing.
|
15987454 |
2005 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Because of the highly vascularized phenotype of breast and ovarian cancers and the contribution of the Neu receptor to the development and progression of these tumors, we investigated the effect of Neu on the expression of the tumor angiogenesis factor VEGF.
|
15302997 |
2004 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
One case showed HER2/neu gene amplification in the associated ductal carcinoma in situ (HER2/CEP17 ratio = 6.5), with no evidence of gene amplification in the invasive tumor (HER2/CEP17 ratio = 1.14).
|
12481013 |
2002 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In breast cancer, increased activity of the HER2 (also known as neu) receptor tyrosine kinase is associated with increased tumor grade, chemotherapy resistance, and decreased patient survival.
|
11359907 |
2001 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These observations led us to hypothesize that h-neu gene plays a role in determination of cell fate in the human central nervous system and may act as a tumor suppressor whose inactivation could be associated with malignant progression of astrocytic tumors.
|
9519875 |
1998 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In contrast, treatment of transgenic mice harboring an activated MMTV-c-neu gene did not result in tumor regression.
|
9418856 |
1998 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
TP53 gene alterations were more frequently present in estrogen receptor (ER)-negative (ER-) tumors (P = 0.04) and in tumors with an amplified HER2/NEU oncogene (P = 0.03).
|
8814449 |
1996 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Previously, we and others have reported high levels of expression of the c-erbB-2/neu gene in non-small cell lung cancer cell lines and primary tumors.
|
7911396 |
1994 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
In total, 93% of the tumors were found to overexpress erbB-2/neu, the highest being in one tumor with erbB-2/neu gene amplification.
|
7905543 |
1994 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Expression of the c-fos protein was seen in 66% of the tumors; expression of the c-myc protein, in 50%; of the c-K-ras protein, in 16%; of the EGF-R protein, in 61%; and of the c-neu protein, in 54% of the tumors.
|
8099529 |
1993 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Amplification and overexpression of the c-erbB-2/neu gene has been shown in certain human tumors and is postulated to be important in human carcinogenesis.
|
1350198 |
1992 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
However, more of the patients whose tumors showed strong membrane staining for NEU antigen suffered relapses of disease by 3 and 4 years than did patients whose tumors showed weak or no membrane staining.
|
1347282 |
1992 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Amplification of the c-myc and HER2/neu genes was found in 20 and 23%, respectively, of primary breast cancer tissues derived from 282 patients (median follow-up, 74 months). c-myc amplification was observed more frequently in larger tumors (P = 0.01) and in lymph node-positive patients (P = 0.01) but was not associated with age, menopausal status, or with differentiation grade or steroid receptor status. c-myc amplification was strongly negatively correlated with HER2/neu amplification (P less than 0.001).
|
1737370 |
1992 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
This study demonstrates tumor cell heterogeneity with regard to neu gene amplification and expression in an ovarian adenocarcinoma, reveals the overexpression of novel neu-complementary transcripts in two independently isolated ovarian adenocarcinoma cell lines, and suggests that neu gene expression is not required for intraperitoneal tumorigenicity of ovarian carcinoma xenografts in a nude mouse model system.
|
1346236 |
1992 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The c-erbB.2/neu gene was identified in two tumors and two ras oncogenes in two other tumors.
|
2560622 |
1990 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The five patients without tumor amplification of the c-neu gene have been followed an average of 31.2 months without evidence of recurrent disease.
|
2227549 |
1990 |